Equity Capital: 588.69 Cr FV: 2.00
Period | MF Net Purchase / (sold) | FII Net |
---|---|---|
LAST 1M | 21,819.21 | 39,849.27 |
LAST 3M | 59,182.99 | 17,912.96 |
LAST 6M | 101,166.54 | 92,564.27 |
LAST 12M | 166,925.45 | 138,096.90 |
Date | Action Type | Ratio |
---|---|---|
Jul 14, 2023 | Dividend | 800 |
Jul 07, 2022 | Dividend | 400 |
Aug 18, 2021 | Dividend | 100 |
AstraZeneca Pharmaceuticals Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 7,640.88 crores, it is incorporated in the year 1979. It has reported standalone sales of Rs. 175.40 crores in June 2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 506820, and also listed on the National Stock Exchange (NSE) with the code ASTRAZEN.
AstraZeneca Pharma deals in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology, and respiratory. It has a workforce of 1400 people across the country. Its manufacturing facility is certified with ISO 14001. AstraZeneca has established a Research & Development facility in Bangalore equipped with a team of 90 employees consisting of scientific experts in the field of regulatory science, clinical science, and patient safety. Its production unit is located in the city of Bengaluru. The company’s plant was the first pharma facility in India to be accredited with Gold Standard Rating under LEED (Leadership in Energy and Environmental Design) certification. The promoters own 75.0% of the stake in the company, Foreign Institutional Investors (FII) own 2.42% of the stake, Domestic Institutional Investors (DII) own 1.02%, and others (such as public & retail investors) hold the balance of 21.56%.
In June 2021, quarterly net revenue was Rs. 175.4 crores, which has decreased by approximately 9.39 % from Rs. 193.58 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 10.24 crores, which has improved sharply and decreased by nearly 45.03% from a net profit of Rs. 18.63 crores in June 2020. In June 2021, the reported operating profit was at Rs. 141.09 crores, which is decreased by 11.79% as compared to an operating profit of Rs. 159.95 crores for the quarter ending in June 2020. From an EPS of Rs. 18.63 in June 2020, the EPS of AstraZeneca Pharmaceuticals Ltd has reduced and reached an EPS of Rs. 10.24 per share in June 2021. ASTRAZEN's stock closed at Rs. 3,056.35 on 27th August’2021 (NSE). AstraZeneca Pharmaceuticals Ltd has returned 11.06% negatively in the last six months and returned 13.50% negatively in the previous year.
Blk N1 12th Flr Manyata Embass, Rachenahalli Outer Ring Road, Bangalore, Karnataka, 560045
Tel | : | 91-080-67748000 |
: | comp.secy:astrazeneca.com | |
Website | : | http://www.astrazeneca.in |
Alpha Systems Pvt Ltd
AGM Date (Month) | : | Aug |
Face Value Equity Shares | : | 2 |
Market Lot Equity Shares | : | 1 |
BSE Code | : | 506820 |
NSE Code | : | ASTRAZEN |
Book Closure Date (Month) | : | |
BSE Group | : | A |
ISIN | : | INE203A01020 |
You can buy Astrazeneca Pharma India Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Astrazeneca Pharma India Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Dec 08, 2023 03:52 PM the closing price of Astrazeneca Pharma India Ltd was ₹ 4,751.30.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 08, 2023 03:52 PM, the market cap of Astrazeneca Pharma India Ltd stood at ₹ 11,878.25.
The latest PE ratio of Astrazeneca Pharma India Ltd as of Dec 08, 2023 03:52 PM is 68.66
The latest PB ratio of Astrazeneca Pharma India Ltd as of Dec 08, 2023 03:52 PM is 0.06
The 52-week high of Astrazeneca Pharma India Ltd is ₹ 4,996.90 while the 52-week low is ₹ 3,098.00